Depression May Be Linked to Impaired Brain Glucose Metabolism — and GLP-1 Drugs Could Help | Research

The takeaway

Major depressive disorder involves widespread impairment of glucose metabolism in the brain and body, and GLP-1 receptor agonists like liraglutide are among several metabolic drugs being explored as potential antidepressant therapies.

Multiple glucose pathways impaired in depression
Depression disrupts glucose metabolism at nearly every level — from cellular uptake through energy production — suggesting it may be fundamentally a metabolic disorder of the brain, not just a neurotransmitter imbalance.

What the researchers found

Patients with MDD show systemic and localized glucose metabolism impairments across multiple processes: glucose uptake, glycoprotein transport, glycolysis, the TCA cycle, and oxidative phosphorylation. These impairments stem from insulin resistance, hyperglycemia-induced damage, oxidative stress, astrocyte dysfunction, and mitochondrial dysfunction.

The downstream consequences include insufficient energy supply to neurons, altered synaptic plasticity, neuronal cell death, and functional/structural damage to brain reward networks — all of which contribute to depressive symptoms. GLP-1 receptor agonists, liraglutide, metformin, topical insulin, and pioglitazone are identified as potential pharmacological interventions that target these metabolic pathways.

Why it matters

Current antidepressants primarily target neurotransmitter systems (serotonin, norepinephrine, dopamine), but roughly one-third of patients don't respond adequately to these treatments. If depression has metabolic roots — as this review argues — then metabolic drugs like GLP-1 receptor agonists could offer an entirely new treatment approach. This is especially relevant given that GLP-1 drugs are already widely available and some patients on them report mood improvements.

How the study worked

This is a narrative review summarizing published research on glucose metabolism impairments in major depressive disorder. The authors synthesized findings from clinical studies, neuroimaging research, and basic science to map the pathophysiological mechanisms connecting metabolic dysfunction to depression, and briefly discussed potential metabolic drug interventions.

What this study cannot tell us

As a narrative review, the paper synthesizes existing evidence but does not present new data or perform systematic analysis. Many of the metabolic drug interventions discussed for depression are based on preclinical data or small clinical studies — large-scale randomized trials specifically testing GLP-1 drugs as antidepressants are still needed. The review also acknowledges that the exact pathogenesis of MDD remains unclear, and metabolic impairment is likely one of many contributing factors.

How to read the evidence

This is a narrative review synthesizing evidence from clinical, neuroimaging, and basic science studies. While the metabolic-depression connection is well-supported by observational data, the therapeutic recommendations (particularly GLP-1 drugs for depression) are largely based on preclinical evidence and small studies, not large-scale clinical trials.

When this study was published

Published in 2025, this review reflects current understanding of the metabolic basis of depression and is timely given the widespread interest in GLP-1 drugs' potential neuropsychiatric effects.

The bigger picture

This review connects to a broader paradigm shift in psychiatry: the recognition that mental disorders often have metabolic underpinnings. The diabetes-depression bidirectional relationship has been well documented, and the success of GLP-1 drugs beyond their original metabolic indications (now extending to heart failure, kidney disease, and potentially neuropsychiatry) reinforces the concept that metabolic health and mental health are deeply intertwined.

Questions still open

Will ongoing trials of GLP-1 receptor agonists show direct antidepressant effects independent of weight loss and improved metabolic health?
Could metabolic biomarkers (such as insulin resistance or brain glucose metabolism imaging) identify which depressed patients would benefit most from metabolic interventions?
Is the glucose metabolism impairment in depression a cause, consequence, or both — and does treating the metabolic dysfunction reverse depressive symptoms?

Common questions

How could diabetes drugs like GLP-1 agonists help with depression?

Depression involves impaired glucose metabolism in the brain — cells can't efficiently take up and use sugar for energy, particularly in regions controlling motivation and reward. GLP-1 receptor agonists improve insulin signaling, reduce inflammation, and may enhance how brain cells process glucose. By addressing the metabolic dysfunction underlying depression rather than just targeting mood-regulating chemicals like serotonin, these drugs could offer a complementary or alternative treatment approach.

Does this mean depression is a metabolic disorder?

Not entirely — depression is complex and involves neurotransmitter, immune, genetic, and psychological factors. But this review argues that metabolic dysfunction, particularly impaired glucose metabolism, is a significant and underappreciated contributor. The bidirectional relationship between depression and diabetes (each increases risk of the other) supports this view. Treating the metabolic component may help patients who don't respond to traditional antidepressants.

Read the original research

Glucose metabolism impairment in major depressive disorder.

Brain research bulletin, 221, 111191

View on PubMed ↗Publisher’s paper ↗

Citation

Meng, Fanhao; Wang, Jing; Wang, Long; Zou, Wei. (2025). Glucose metabolism impairment in major depressive disorder.. Brain research bulletin, 221, 111191. https://doi.org/10.1016/j.brainresbull.2025.111191